False equivalence. The insinuation is that RAC strategically...

False equivalence.

The insinuation is that RAC strategically canned RC110 the moment RC220 was developed to better spend capital elsewhere, resulting in schedule blow-outs.

That's not the case.

According to RAC's own announcements, RC110 should have been dosed in EML AND BC patients, in a low dose setting, with the aim of therapeutically validating Zan as an FTO inhibitor PRIOR to FY23. RC220 wasn't announced until Q2 FY23.

RAC couldn't get there. This validation would have been immensely valuable and the company wouldn't be raising cash at a pittance today. If we're throwing around our preferred scenarios then this is my nomination.